Medovex Corporation Names Manfred Sablowski as Senior VP Sales & Marketing
ATLANTA, GA -- (Marketwired) -- 02/18/15 -- Medovex Corporation (NASDAQ: MDVX), a developer of medical technology products including the DenerveX™ device, announced today that Manfred Sablowski has been named as Senior VP Sales and Marketing.
Mr. Sablowski will be responsible for leading and coordinating the company's worldwide sales and marketing functions, in addition to developing and implementing its sales and marketing strategy.
"We're pleased to have added a seasoned sales executive like Manfred to our team. His 20 years of senior management experience in the medical technology industry makes him a natural choice to lead our worldwide sales initiatives. With the recent naming of Jeff Wright as our new CFO and now Manfred as SVP of Sales and Marketing, we continue to build a strong foundation of experienced and accomplished executives who together are squarely focused on value creation for our shareholders," said Jarrett Gorlin, CEO of Medovex.
Prior to joining Medovex, Mr. Sablowski held several executive level positions such as General Manager at Valleylab/Pfizer, Europe; VP Sales and Marketing Dornier Medizin Technik, Europe; VP Sales and Marketing Bovie Medical-Worldwide. He also served as Board Member and Vice President/COO for Trod Medical, a successful venture backed start-up, in which he was involved from its inception.
He is the principal of FMS MedTech Consulting, a consulting firm focusing on strategic planning for the international businesses in the medical industry (Europe and U.S.). Mr. Sablowski holds a bachelor of science, a diploma as chemical engineer and earned a MBA in Germany.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement:
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Source: Medovex Corporation
Released February 18, 2015